AAAAAA
Results: 1-25/1504
Authors:
ROTHENBERG ML
Citation: Ml. Rothenberg, COLORECTAL-CANCER - THERAPEUTIC UPDATE - INTRODUCTION, Seminars in oncology, 25(5), 1998, pp. 1-1
Authors:
BENSON AB
Citation: Ab. Benson, THERAPY FOR ADVANCED COLORECTAL-CANCER, Seminars in oncology, 25(5), 1998, pp. 2-11
Authors:
MITCHELL EP
Citation: Ep. Mitchell, ROLE OF CARCINOEMBRYONIC ANTIGEN IN THE MANAGEMENT OF ADVANCED COLORECTAL-CANCER, Seminars in oncology, 25(5), 1998, pp. 12-20
Authors:
GOLDBERG RM
Citation: Rm. Goldberg, IS REPEATED TREATMENT WITH A 5-FLUOROURACIL-BASED REGIMEN USEFUL IN COLORECTAL-CANCER, Seminars in oncology, 25(5), 1998, pp. 21-28
Authors:
HENDERSON CA
Citation: Ca. Henderson, THERAPEUTIC OPTIONS FOR THE TREATMENT OF COLORECTAL-CANCER FOLLOWING 5-FLUOROURACIL FAILURE, Seminars in oncology, 25(5), 1998, pp. 29-38
Authors:
ROTHENBERG ML
Citation: Ml. Rothenberg, EFFICACY AND TOXICITY OF IRINOTECAN IN PATIENTS WITH COLORECTAL-CANCER, Seminars in oncology, 25(5), 1998, pp. 39-46
Authors:
VONHOFF DD
Citation: Dd. Vonhoff, PROMISING NEW AGENTS FOR TREATMENT OF PATIENTS WITH COLORECTAL-CANCER, Seminars in oncology, 25(5), 1998, pp. 47-52
Authors:
BERG D
Citation: D. Berg, MANAGING THE SIDE-EFFECTS OF CHEMOTHERAPY FOR COLORECTAL-CANCER, Seminars in oncology, 25(5), 1998, pp. 53-59
Authors:
PERRY MC
Citation: Mc. Perry, INTRODUCTION - PREVENTING THE TOXICITY OF CHEMOTHERAPY, Seminars in oncology, 25(5), 1998, pp. 521-521
Authors:
MARKMAN M
Citation: M. Markman, AMIFOSTINE IN REDUCING CISPLATIN TOXICITY, Seminars in oncology, 25(5), 1998, pp. 522-524
Authors:
SPEYER J
WASSERHEIT C
Citation: J. Speyer et C. Wasserheit, STRATEGIES FOR REDUCTION OF ANTHRACYCLINE CARDIAC TOXICITY, Seminars in oncology, 25(5), 1998, pp. 525-537
Authors:
WILKES JD
Citation: Jd. Wilkes, PREVENTION AND TREATMENT OF ORAL MUCOSITIS FOLLOWING CANCER-CHEMOTHERAPY, Seminars in oncology, 25(5), 1998, pp. 538-551
Authors:
JOHNSTON EM
CRAWFORD J
Citation: Em. Johnston et J. Crawford, HEMATOPOIETIC GROWTH-FACTORS IN THE REDUCTION OF CHEMOTHERAPEUTIC TOXICITY, Seminars in oncology, 25(5), 1998, pp. 552-561
Authors:
DORR VJ
Citation: Vj. Dorr, A PRACTITIONERS GUIDE TO CANCER-RELATED ALOPECIA, Seminars in oncology, 25(5), 1998, pp. 562-570
Authors:
JILANI SM
GLASPY JA
Citation: Sm. Jilani et Ja. Glaspy, IMPACT OF EPOETIN-ALPHA IN CHEMOTHERAPY-ASSOCIATED ANEMIA, Seminars in oncology, 25(5), 1998, pp. 571-576
Authors:
GRALLA RJ
Citation: Rj. Gralla, ANTIEMETIC THERAPY, Seminars in oncology, 25(5), 1998, pp. 577-583
Authors:
HAUSHEER FH
KANTER P
CAO S
HARIDAS K
SEETHARAMULU P
REDDY D
PETLURU P
ZHAO M
MURALI D
SAXE JD
YAO S
MARTINEZ N
ZUKOWSKI A
RUSTUM YM
Citation: Fh. Hausheer et al., MODULATION OF PLATINUM-INDUCED TOXICITIES AND THERAPEUTIC INDEX - MECHANISTIC INSIGHTS AND FIRST-GENERATION AND 2ND-GENERATION PROTECTING AGENTS, Seminars in oncology, 25(5), 1998, pp. 584-599
Authors:
BUNN PA
LECHEVALIER T
Citation: Pa. Bunn et T. Lechevalier, LUNG-CANCER RESEARCH - NEW COMBINATIONS AND THE EMERGING ROLE OF GEMCITABINE, Seminars in oncology, 25(4), 1998, pp. 1-1
Authors:
BUNN PA
VOKES EE
LANGER CJ
SCHILLER JH
Citation: Pa. Bunn et al., AN UPDATE ON NORTH-AMERICAN RANDOMIZED STUDIES IN NONSMALL CELL LUNG-CANCER, Seminars in oncology, 25(4), 1998, pp. 2-10
Authors:
GIACCONE G
MANEGOLD C
ROSELL R
GATZEMEIER U
QUOIX E
Citation: G. Giaccone et al., AN UPDATE ON EUROPEAN RANDOMIZED STUDIES IN NONSMALL CELL LUNG-CANCER, Seminars in oncology, 25(4), 1998, pp. 11-17
Authors:
MANEGOLD C
Citation: C. Manegold, SINGLE-AGENT GEMCITABINE VERSUS CISPLATIN ETOPOSIDE IN PATIENTS WITH INOPERABLE, LOCALLY ADVANCED, OR METASTATIC NONSMALL CELL LUNG-CANCER/, Seminars in oncology, 25(4), 1998, pp. 18-22
Authors:
CRINO L
MOSCONI AM
SCAGLIOTTI GV
SELVAGGI G
RINALDI M
DELLAGIULIA M
GRIDELLI C
CALANDRI C
DEMARINIS F
NOSEDA M
TONATO M
Citation: L. Crino et al., GEMCITABINE AS 2ND-LINE TREATMENT FOR RELAPSING OR REFRACTORY ADVANCED NONSMALL CELL LUNG-CANCER - A PHASE-II TRIAL, Seminars in oncology, 25(4), 1998, pp. 23-26
Authors:
ROSELL R
TONATO M
SANDLER A
Citation: R. Rosell et al., THE ACTIVITY OF GEMCITABINE PLUS CISPLATIN IN RANDOMIZED TRIALS IN UNTREATED PATIENTS WITH ADVANCED NONSMALL CELL LUNG-CANCER, Seminars in oncology, 25(4), 1998, pp. 27-34
Authors:
ABRATT RP
SANDLER A
CRINO L
STEWARD WP
SHEPHERD FA
GREEN MR
NGUYEN B
PETERS GJ
Citation: Rp. Abratt et al., COMBINED CISPLATIN AND GEMCITABINE FOR NONSMALL CELL LUNG-CANCER - INFLUENCE OF SCHEDULING ON TOXICITY AND DRUG-DELIVERY, Seminars in oncology, 25(4), 1998, pp. 35-43
Authors:
DOMBERNOWSKY P
GIACCONE G
SANDLER A
SCHWARTSMANN G
Citation: P. Dombernowsky et al., GEMCITABINE AND PACLITAXEL COMBINATIONS IN NONSMALL CELL LUNG-CANCER, Seminars in oncology, 25(4), 1998, pp. 44-50